Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1994 Apr;32(4):1104–1106. doi: 10.1128/jcm.32.4.1104-1106.1994

Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.

R N Jones 1
PMCID: PMC267197  PMID: 8027323

Abstract

FK-037, a new parenteral cephalosporin, was tested against 483 organisms from clinical infections to establish preliminary susceptibility testing criteria with 30-micrograms disks. The proposed breakpoint zone diameters were > or = 17 mm (MIC correlate, < or = 8 micrograms/ml) for the susceptible category and < or = 13 mm (MIC correlate, > or = 32 micrograms/ml) for the resistant category. These interpretive guidelines produced no very major (false-susceptible) errors, 2.9% major (false-resistant) errors, and 6.2% minor errors for a total absolute agreement between methods of 90.9%.

Full text

PDF
1104

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fu K. P., Foleno B. D., Lafredo S. C., LoCoco J. M., Isaacson D. M. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1993 Feb;37(2):301–307. doi: 10.1128/aac.37.2.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fuchs P. C., Jones R. N., Barry A. L. In vitro antibacterial spectrum of E1040 compared with those of cefpirome and ceftazidime and disk diffusion interpretive criteria for E1040. Antimicrob Agents Chemother. 1990 May;34(5):914–917. doi: 10.1128/aac.34.5.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. doi: 10.1128/aac.27.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jones R. N., Thornsberry C., Barry A. L. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984 Jun;25(6):710–718. doi: 10.1128/aac.25.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Neu H. C., Chin N. X., Huang H. B. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin. Antimicrob Agents Chemother. 1993 Mar;37(3):566–573. doi: 10.1128/aac.37.3.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Sanchez M. L., Jones R. N. Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample. J Antimicrob Chemother. 1993 Oct;32(4):654–656. doi: 10.1093/jac/32.4.654. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES